Cochrane · systematic review · CD013257
Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without bevacizumab for people with advanced non‐small cell lung cancer
Ferrara, R, Imbimbo, M, Malouf, R, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
10
current version
GRADE rated
7
No studies
3
Included studies
NR
No studies 3 · 30%Ungraded 0 · 0%Very low 0 · 0%Low 5 · 50%Moderate 2 · 20%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlySingle‐immune checkpoint inhibitors (ICIs) compared to chemotherapy for people with advanced non‐small cell lung cancer (NSCLC)
Population: People with advanced non‐small cell lung cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival (OS) Single‐immune checkpoint inhibitors (ICIs) vs chemotherapy | HR 0.68 [0.6, 0.76] | 6 studies · 2111 participants | Moderate Downgraded: risk of bias |
Progression‐free survival (PFS) Single‐immune checkpoint inhibitors (ICIs) vs chemotherapy | HR 0.68 [0.51, 0.88] | 5 studies · 1886 participants | Low Downgraded: risk of bias |
Overall response rate (ORR) Single‐immune checkpoint inhibitors (ICIs) vs chemotherapy | RR 1.4 [1.12, 1.75] | 4 studies · 1672 participants | Low Downgraded: risk of bias |
Adverse Events grade 3‐4 Single‐immune checkpoint inhibitors (ICIs) vs chemotherapy | RR 0.41 [0.33, 0.5] | 5 studies · 3346 participants | Low Downgraded: risk of bias |
QOL‐C30 GHS/QOL (range 0‐100) ‐ change from baseline to week 15 Single‐immune checkpoint inhibitors (ICIs) vs chemotherapy | RR 1.51 [1.08, 2.1] | 1 study · 297 participants | Low Downgraded: risk of bias |
Combined immune checkpoint inhibitors (ICIs) compared to chemotherapy for people with advanced non‐small cell lung cancer (NSCLC)
Population: people with advanced non‐small cell lung cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall Survival (OS) Combined immune checkpoint inhibitors (ICIs) vs chemotherapy | HR 0.72 [0.59, 0.89] | 2 studies · 612 participants | Moderate Downgraded: risk of bias |
Progression‐free survival (PFS) Combined immune checkpoint inhibitors (ICIs) vs chemotherapy | no estimate extracted | NR | No studies |
Overall response rate (OSR) Combined immune checkpoint inhibitors (ICIs) vs chemotherapy | no estimate extracted | NR | No studies |
Adverse Events grade 3 to 4 Combined immune checkpoint inhibitors (ICIs) vs chemotherapy | RR 0.78 [0.55, 1.09] | 2 studies · 1869 participants | Low Downgraded: risk of bias |
HRQoL Combined immune checkpoint inhibitors (ICIs) vs chemotherapy | no estimate extracted | NR | No studies |
Single‐immune checkpoint inhibitors (ICIs) compared to chemotherapy for people with advanced non‐small cell lung cancer (NSCLC)
Population: People with advanced non‐small cell lung cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival (OS) Single‐immune checkpoint inhibitors (ICIs) vs chemotherapy | HR 0.68 [0.6, 0.76] | 6 studies · 2111 participants | Moderate Downgraded: risk of bias |
Progression‐free survival (PFS) Single‐immune checkpoint inhibitors (ICIs) vs chemotherapy | HR 0.68 [0.51, 0.88] | 5 studies · 1886 participants | Low Downgraded: risk of bias |
Overall response rate (ORR) Single‐immune checkpoint inhibitors (ICIs) vs chemotherapy | RR 1.4 [1.12, 1.75] | 4 studies · 1672 participants | Low Downgraded: risk of bias |
Adverse Events grade 3‐4 Single‐immune checkpoint inhibitors (ICIs) vs chemotherapy | RR 0.41 [0.33, 0.5] | 5 studies · 3346 participants | Low Downgraded: risk of bias |
QOL‐C30 GHS/QOL (range 0‐100) ‐ change from baseline to week 15 Single‐immune checkpoint inhibitors (ICIs) vs chemotherapy | RR 1.51 [1.08, 2.1] | 1 study · 297 participants | Low Downgraded: risk of bias |
Combined immune checkpoint inhibitors (ICIs) compared to chemotherapy for people with advanced non‐small cell lung cancer (NSCLC)
Population: people with advanced non‐small cell lung cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall Survival (OS) Combined immune checkpoint inhibitors (ICIs) vs chemotherapy | HR 0.72 [0.59, 0.89] | 2 studies · 612 participants | Moderate Downgraded: risk of bias |
Progression‐free survival (PFS) Combined immune checkpoint inhibitors (ICIs) vs chemotherapy | no estimate extracted | NR | No studies |
Overall response rate (OSR) Combined immune checkpoint inhibitors (ICIs) vs chemotherapy | no estimate extracted | NR | No studies |
Adverse Events grade 3 to 4 Combined immune checkpoint inhibitors (ICIs) vs chemotherapy | RR 0.78 [0.55, 1.09] | 2 studies · 1869 participants | Low Downgraded: risk of bias |
HRQoL Combined immune checkpoint inhibitors (ICIs) vs chemotherapy | no estimate extracted | NR | No studies |